---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-24-000069"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:44:42.500859+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics Q3 net loss $10.2M, cash $217.2M; LNZ100 NDA accepted, PDUFA Aug 8, 2025

## Summary
- Net loss $10.2M ($0.38/share) for Q3 2024 vs $18.9M ($9.62/share) in Q3 2023.
- Cash, equivalents and marketable securities $217.2M as of Sept 30, 2024; cash runway to post-launch positive operating cash flow.
- FDA accepted NDA for LNZ100 (aceclidine) for presbyopia; PDUFA target action date Aug 8, 2025.
- Positive topline Phase 3 data from China: 74% of patients achieved 3-line or greater improvement at 3 hours (p<0.0001).
- Completed $30M private placement with Ridgeback Capital in July 2024.

## SEC filing metadata
- accession: 0001815776-24-000069
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000069/0001815776-24-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000069/lenz-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-24-000069
- JSON: https://secwatch.observer/filing/0001815776-24-000069.json
- Plain text: https://secwatch.observer/filing/0001815776-24-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.